UBX-363

N/A

Report date: 2024/02/26 11:15:19
NME

Base Information

Drug NameUBX-363
Drug Alias NameUBX-363
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase LCK degraders
TargetsTyrosine-protein kinase LCK
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUbix Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUbix Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A